_1777294237270_124456903.png&w=48&q=75){kind=small}
Alvalon Pharma extends 50m Riyal credit with Al-Inma
Avalon Pharma, formerly known as the Middle East Pharmaceuticals Company, announces the renewal of a credit facilities agreement with Bank Alinma valued at 50 million Saudi Riyals. These facilities aim to support working capital and cover capital expenditures to enhance operational efficiency and back expansion plans, with a financing period of up to one year starting from August 2026. The company affirms its commitment to Shariah compliance and will provide promissory note guarantees to ensure the fulfillment of its financial obligations. There are no related-party involved in the agreement. This initiative is part of the company's strategy to diversify its funding sources and support the pharmaceutical sector in the Kingdom as part of Vision 2030.
Notice: This Is an AI-Generated Summary
Comments (0)